Pharmacy Podcast Network

Your ability to produce Nitric Oxide (N-O) declines rapidly as you age. Berkeley Life Professional’s proprietary dietary nitrate blend provides the plant-based bio-equivalents of a leafy green diet in each two capsule dose helping you maintain Nitric Oxide levels as you age. This interview with Berkeley Life CEO John Halbert is a terrific testimonial to the importance of the supplement and to the revenue opportunity for community pharmacies. RxSafe, RMS, and Berkeley Life will be sponsoring the 2022 Pharmacy Profit Summit in Dallas Texas hosted by DiversifyRx.

Learn more: https://www.berkeleylife.com/

Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Greco DeValencia of Live Oak Bank and Owen BonDurant and Rich Danhof of Independent Rx discuss the recent rate hikes, how it affects current pharmacy owners and owners to be and what to be concerned about beyond just the headlines of rising rates.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Accreditation and support statement:

· PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.

· This activity is supported by educational grant from GlaxoSmithKline.

Objectives

• Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer.

• Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives

·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV.

·      Describe the role of pharmacists in improving PrEP uptake in the United States. 

 

 

Faculty:

Drew W. Cates, PharmD, AAHIVP,

Educational Manager

SynerGrx

Chamblee, Georgia 

Faculty, has the following financial relationships with commercial interests to disclose:

Speaker's Bureau: Gilead

 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023.

This activity is supported by an educational grant from ViiV.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives

• Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC)

• Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations

 

Josiah D. Land, PharmD, BCOP

Clinical Pharmacy Specialist – Thoracic Medical Oncology

Department of Pharmacy

Memorial Sloan Kettering Cancer Center

New York, New York

 

Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Consultant (advisory board): Bristol Myers Squibb

 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.

 

This activity is supported by educational funding provided by Amgen.

Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode interviews Dr Alyson McGregor, MD Professor of Emergency Medicine and Associate Dean of Clinical Faculty Affairs and Development at University of South Carolina School of Medicine Greenville. 

Dr McGregor is a sex and gender expert, educator and advocate. Dr McGregor discusses her book, Sex Matters: How Male-Centric Medicine Endangers Women's Health and What We Can Do About It. 

https://www.alysonmcgregormd.com/

@amcgregormd

Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives

·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens

·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC

 

Faculty:

Paul Forsberg, PharmD, MHA, BCOP

Director of Pharmacy

Minnesota Oncology

St. Paul, Minnesota

 

Latha Radhakrishnan, PharmD, BCOP

Clinical Oncology Pharmacist

The University of Illinois Hospital and Health Sciences System

Clinical Assistant Professor

University of Illinois at Chicago College of Pharmacy

Chicago, Illinois

 

Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Epizyme

Speakers Bureau: AstraZeneca

 

Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Taiho, Novartis, Exelixis

Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis

 

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.

 

This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

 https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations

Learn more about your ad choices. Visit megaphone.fm/adchoices

4 Can't Miss Trends about Digital Engagement! Coming up on Friday's livestream of the DarshanTalks Podcast with host Darshan Kulkarni and guest Ritesh Patel, originally streamed on July 15th, 2022. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to Dexcom G6 User Guide. For product-related questions, please refer to instructions for use. For complete safety information, go to dexcom.com/safety-information Smart devices are sold separately. For a list of compatible smart device visit Dexcom.com/compatibility

 Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

 Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.

Dexcom G6 System User Guide

 Safety Information https://www.dexcom.com/safety-information

 Dexcom Follow app: The Dexcom G6 App allows you to share your glucose data with up to 10 people. By downloading the Dexcom Follow App, followers can view your glucose data directly from their smart device† whether they live down the street or across the country*.

Connectivity – basics (https://provider.dexcom.com/dexcom-cgm/collaborators)

About Dexcom https://www.dexcom.com/about-Dexcom

Beacon Health System Resources

Dexcom Patient Training and Resources

Dexcom Prescribing Information

Brief Safety Statement

Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

The web-based Dexcom CLARITY software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.

Dexcom, Dexcom Follow, Dexcom CLARITY, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

References:

1.    William H. Polonsky, Emily C. Soriano, and Addie L. Fortmann. Diabetes Technology & Therapeutics. Ahead of print http://doi.org/10.1089/dia.2021.0526

2.    Shah VN, et al. Diabetes Technology & Therapeutics. 2018;20(S1):A-27 DOI: 10.1089/dia.2018.0143

3.    Kaushik S, et al. Diabetes. 2020 Jun;69(Supplement 1) https://doi.org/10.2337/db20-79-LB 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Solid PR practices call for changing the conversation to one's advantage, but PCMA's recent OpEds based on a paid-for white paper are more than suspect. 

Listen in as lobbyist & managing partner of Public Policy Partners Meghaen Della'Artino, and General Counsel for American Pharmacies Miguel Rodriguez, speak with PUTTcast host Monique Whitney about strategy, the current political arena, and how the power of grassroots and a constituent's voice can overcome the most well-funded PBM politics.

Learn more about your ad choices. Visit megaphone.fm/adchoices